"India Pharmaceuticals & Healthcare Report Q4 2015" is now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Wed Sep 23 2015

Internationalisation of Indian generic drugmakers will continue. This is facilitated by the growing use of generic substitution as a tool of cost containment globally, as governments seek to curb rising healthcare expenditure. Key risks include the difficulties in ensuring quality manufacturing and medicine pricing pressures.

Headline Expenditure Projections

Pharmaceuticals: INR954bn (USD16bn) in 2014 to INR1,066bn (17bn) by 2015; +11.7% in local currency terms and 7.0% in US dollar terms. Historic data revised down after new data from AIOCD AWACS.
Healthcare: INR5,085bn (USD83bn) in 2014 to INR5,716bn (USD90bn) by 2015; +12.4% in local currency terms and 7.6% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1044794_india_pharmaceuticals.aspx?afid=301

Risk/Reward Index

India's pharmaceutical market is the ranks as the tenth most attractive amongst 19 other countries in the Asia Pacific region. Scoring 53.0 out of 100.0 for our BMI Pharmaceutical Risk/Reward Index in Q415, the country's high market expenditure (scoring 16.0 out of 20.0) is weighed down by the low spending per capita (scoring 1.2 out of 12) as well as the high risks involved including low patent respect (scoring 2.1 out of 7.0). Despite India's rapid development, numerous problems are present - such as high levels of poverty and illiteracy, persistent malnutrition, and environmental degradation - and continue to thwart India's pre-eminence.

Key Trends And Developments

In July 2015, Indian authorities extended price control on 39 more medicines used to treat diseases such as diabetes, infections and digestive orders among others. According to industry estimates, the price reductions are expected to range from 5% to 40% depending on the drug category.

That same month, India's supreme court said that a group seeking to lower medicine prices should be allowed to petition the country's government to review its pricing policy for medicines deemed essential.

The India Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's India Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the India pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for India, to test other views - a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Indian pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »